INZY

Inozyme Pharma, Inc. [INZY] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

INZY Stock Summary

Top 10 Correlated ETFs

INZY

Top 10 Correlated Stocks

INZY

In the News

INZY Financial details

Company Rating
-
Market Cap
317.51M
Income
-70M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
59
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-4.02
Forward P/E
-
PEG
1.88
P/S
-
P/B
1.65
P/C
-
P/FCF
-4.32
Quick Ratio
15.68
Current Ratio
16.36
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.36
EPS next Y
-
EPS next Q
-
EPS this Y
-20.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
20.69%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-66.67%
Inst Own
-
Inst Trans
-
ROA
-32%
ROE
-54%
ROC
-0.37%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.689-7.795
52W High
-83.57%
52W Low
-42.5%
RSI
58
Rel Volume
0.91
Avg Volume
644.07K
Volume
585.65K
Perf Week
11.65%
Perf Month
15.14%
Perf Quarter
-71.74%
Perf Half Y
-75.94%
-
-
-
-
Beta
1.367
-
-
Volatility
0.06%, 0.07%
Prev Close
8.49%
Price
1.15
Change
19.53%

Something similar

Top by Market Cap
MIX.JO
EMBASSY.NS
FB2A.DE
3V64.DE
VFINX
Top Correlated ETFs
BETZ
SCJ
GWX
DFJ
JPXN
Top Correlated Stocks
3877.T
HMC
CELC
000639.SZ
OCUL
Similar Market Cap
6033.HK
CALB
ANORA.HE
AFM.L
DWX

Company Profile

Healthcare Biotechnology
  • Volume Average 644.07K
  • Market Capitalization 317.51M
  • Employee 59
  • CEO Dr. Douglas A. Treco Ph.D.
  • Headquarters Boston,MA,US
  • IPO Date 2020-07-24
  • Website https://www.inozyme.com

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.